Recent news on Leukine

Former Immunex Management Team Chosen to Head-Up CTI Subsidiary ...  -  May 14, 2007
PharmaLive.com (press release),..."We have put together some of the scientists from the team who participated in the development of biologics at Immunex, such as Leukine(R) and Enbrel(R),

Favrille Reports First Quarter 2007 Financial Results  -  May 10, 2007
Genetic Engineering News (press release),This agreement helps pave the way for commercialization, including reimbursement, of FavId in combination with Berlex's Leukine(R) (sargramostim, GM-CSF),

Onmark Signs Exclusive Contracts with Pfizer and Berlex for ...  -  Apr 3, 2007
Earthtimes.org...today announced that it has signed new contracts with Pfizer for Camptosar(R) (irinotecan) and with Berlex for Leukine(R) (sargramostim).

CoGenesys Expands Clinical Programs With Initiation Of Phase 1-2a ...  -  Mar 29, 2007
Medical News Today (press release),Three products have been approved for marketing in the United States: Amgen's Neupogen(R) and Neulasta(R), and Schering AG's Leukine(R).

Lynnwood lab not part of Bayer layoffs  -  Mar 3, 2007
HeraldNet,The plant, which is preparing for the long regulatory certification process, plans to produce Leukine, an artificial form of a naturally occurring growth

Diversa to offer convertible notes  -  Mar 22, 2007
San Diego Union Tribune,German pharmaceutical company Bayer Schering Pharma AG to study the use of the San Diego-based company's immunotherapy drug Favid with Berlex's Leukine.

Novel Treatment Strategy Evaluating Rituxan® plus Leukine® in ...  -  Feb 5, 2007
Cancer Consultants (press release),A clinical trial that will evaluate the effectiveness of the addition to Leukine® (sargramostim) to Rituxan® (rituximab) in patients with follicular

Favrille Reports Fourth Quarter and Year End 2006 Financial Results  -  Feb 18, 2007
Drug Newswire (press release),Leukine is a. appropriate patients by enhancing immune cell function. GM-CSF has. trials of active immunotherapies. GM-CSF was first used in an early

Favrille Announces Agreement With Berlex, Inc. Regarding Use of ...  -  Feb 14, 2007
PR Newswire (press release),Leukine is a recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF), a growth factor that is currently used to help fight infections in

Favrille Reports Fourth Quarter and Year End 2006 Financial Results  -  Feb 15, 2007
Earthtimes.orgRecent Highlights * Announced Agreement with Berlex Regarding Use of FavId in Combination with Leukine. Favrille entered into an agreement with Berlex,

Favrille Reports Fourth Quarter and Year End 2006 Financial Results  -  Feb 15, 2007
MSN MoneyAnnounced Agreement with Berlex Regarding Use of FavId in Combination with Leukine. Favrille entered into an agreement with Berlex, Inc., a US affiliate of

Favrille Inks Deal With Berlex  -  Feb 14, 2007
Houston Chronicle,Leukine is aimed at improving immune cell function with the goal of fighting infections. Shares of Favrille rose 22 cents, or 7 percent, to reach $3.39 on

Favrille Inks Deal With Berlex  -  Feb 14, 2007
Forbes,Leukine is aimed at improving immune cell function with the goal of fighting infections. Shares of Favrille (nasdaq: FVRL - news - people ) rose 22 cents,

Market Report -- In Play (FVRL)  -  Feb 14, 2007
MSN MoneyFavrille announces agreement with Berlex regarding use of FavId in combination with Leukine in B-Cell non-hodgkin's lymphoma Co announces it has entered

Growth Factors May Increase Risk of AML and MDS in Post-menopausal ...  -  Feb 15, 2007
Cancer Consultants (press release),One group of patients also received growth factors Neupogen® (filgrastim) or Leukine® (sargramostim), and the other group did not receive growth factors.

Growth Factors May Increase Risk of Secondary AML and MDS in Post ...  -  Feb 9, 2007
Cancer Consultants (press release),The patients had stage I-III breast cancer with positive lymph nodes and had received adjuvant chemotherapy with or without Neupogen or Leukine.

(PRN) - Personality Study Shows That Web-Daters Are Often Outgoing ...  -  Feb 14, 2007
Bolsamania.com,...(PRN) - Favrille Announces Agreement With Berlex, Inc. Regarding Use of FavId(R) in Combination With Leukine(R) (sargramostim) in B-Cell Non-Hodgkin's

Amgen infection drug tied to higher cancer risk  -  Feb 7, 2007
Los Angeles Times,The study also found a similar risk among patients taking Bayer Schering's Leukine, which is also prescribed to fight infections in chemo patients.

Immunity Boosters Linked to Leukemia  -  Feb 6, 2007
WebMDBut the drugs, G-CSF (such as Neupogen) and GM-CSF (such as Leukine), may themselves cause rare cases of leukemia, find Columbia University researcher Dawn

Biotech Day In Review: Osiris Stem Cells Treatment Has Unexpected ...  -  Feb 15, 2007
Seeking Alpha,Favrille (FVRL) will collaborate with the Berlex unit of Bayer (BAY) to study the combination of FavID, the cancer immunotherapy from Favrille, and Leukine,

Pharma Sector: Few Newsmakers Of The Week - Schwarz Pharma ...  -  Jan 6, 2007
Trading Markets,Amgen's Neupogen and Neulasta and Schering AG's Leukine are the only three products approved for marketing in the United States for decreasing the incidence

Diamics Appoints Christine A. Meda as President  -  Jan 5, 2007
Genetic Engineering News (press release),...and as Medical Affairs Director, responsible for clinical trials for their hematological oncology drugs: Fludara, CamPath and Leukine.

CoGenesys Files To Begin Clinical Trials Of Neugranin For The ...  -  Jan 5, 2007
Medical News Today (press release),Three products have been approved for marketing in the United States: Amgen's Neupogen(R) and Neulasta(R), and Schering AG's Leukine(R).

CoGenesys Files to Begin Clinical Trials of Neugranin for the ...  -  Jan 4, 2007
PipelineReview.com (press release),Three products have been approved for marketing in the United States: Amgen's Neupogen® and Neulasta®, and Schering AG's Leukine®.

Abbott/Eisai's Humira and UCB's Cimzia Will Drive Sales of TNF ...  -  Dec 20, 2006
PR Newswire (press release),These biological agents include Berlex/Schering AG's Leukine and Abbott's ABT-874, both of which utilize novel mechanisms of action and will provide

Rituxan® plus Leukine® Promising for Low-grade Lymphomas  -  Dec 11, 2006
Cancer Consultants (press release),Leukine is a growth factor, or cytokine, which is an agent that can stimulate the immune system to help fight or prevent infection or disease.

Rituxan® and Leukine® Promising for Low-Grade Lymphomas  -  Dec 8, 2006
Cancer Consultants (press release),Leukine has been shown to enhance the expression of CD20 on B cells, to potentiate antibody-dependent cellular cytotoxicity, to increase dendritic cell

Novel Treatment Strategy Evaluating Rituxan® plus Leukine® in ...  -  Dec 4, 2006
Cancer Consultants (press release),A clinical trial that will evaluate the effectiveness of the addition to Leukine® (sargramostim) to Rituxan® (rituximab) in patients with follicular

Pharma-biotech eyes 30% rise in new facility construction  -  Dec 12, 2006
Reliable Plant Magazine,The company will use the facility to produce Leukine, a cancer treatment. In the Midwest, animal nutritionals company MVP Laboratories (Omaha, Neb.

Abbott/Eisai's Humira and UCB's Cimzia Will Drive Sales of TNF ...  -  Dec 20, 2006
PR Newswire (press release),These biological agents include Berlex/Schering AG's Leukine and Abbott's ABT-874, both of which utilize novel mechanisms of action and will provide

Positive Phase II Clinical Trial Results with HER2/neu Vaccine  -  Dec 15, 2006
PipelineReview.com (press release),E75 is administered as a vaccine consisting of the peptide mixed with GM-CSF (sargramostim or Leukine®) as an immunoadjuvant and administered intradermally

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional